241 related articles for article (PubMed ID: 28611197)
1. Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin.
Rajeshkumar NV; Yabuuchi S; Pai SG; De Oliveira E; Kamphorst JJ; Rabinowitz JD; Tejero H; Al-Shahrour F; Hidalgo M; Maitra A; Dang CV
Clin Cancer Res; 2017 Sep; 23(18):5639-5647. PubMed ID: 28611197
[No Abstract] [Full Text] [Related]
2. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
Elgogary A; Xu Q; Poore B; Alt J; Zimmermann SC; Zhao L; Fu J; Chen B; Xia S; Liu Y; Neisser M; Nguyen C; Lee R; Park JK; Reyes J; Hartung T; Rojas C; Rais R; Tsukamoto T; Semenza GL; Hanes J; Slusher BS; Le A
Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5328-36. PubMed ID: 27559084
[TBL] [Abstract][Full Text] [Related]
3. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
4. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors.
Stalnecker CA; Grover KR; Edwards AC; Coleman MF; Yang R; DeLiberty JM; Papke B; Goodwin CM; Pierobon M; Petricoin EF; Gautam P; Wennerberg K; Cox AD; Der CJ; Hursting SD; Bryant KL
Cancer Res; 2022 Feb; 82(4):586-598. PubMed ID: 34921013
[TBL] [Abstract][Full Text] [Related]
6. Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient-Derived Xenografts.
Mohamed Suhaimi NA; Phyo WM; Yap HY; Choy SHY; Wei X; Choudhury Y; Tan WJ; Tan LAPY; Foo RSY; Tan SHS; Tiang Z; Wong CF; Koh PK; Tan MH
Mol Cancer Ther; 2017 Sep; 16(9):2035-2044. PubMed ID: 28533437
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
Pham NA; Radulovich N; Ibrahimov E; Martins-Filho SN; Li Q; Pintilie M; Weiss J; Raghavan V; Cabanero M; Denroche RE; Wilson JM; Metran-Nascente C; Borgida A; Hutchinson S; Dodd A; Begora M; Chadwick D; Serra S; Knox JJ; Gallinger S; Hedley DW; Muthuswamy L; Tsao MS
Sci Rep; 2021 May; 11(1):10619. PubMed ID: 34011980
[TBL] [Abstract][Full Text] [Related]
9. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
10. Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer.
Masoud R; Reyes-Castellanos G; Lac S; Garcia J; Dou S; Shintu L; Abdel Hadi N; Gicquel T; El Kaoutari A; Diémé B; Tranchida F; Cormareche L; Borge L; Gayet O; Pasquier E; Dusetti N; Iovanna J; Carrier A
Cell Rep Med; 2020 Nov; 1(8):100143. PubMed ID: 33294863
[TBL] [Abstract][Full Text] [Related]
11. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
[TBL] [Abstract][Full Text] [Related]
12. Overall survival of pancreatic ductal adenocarcinoma is doubled by
Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
[No Abstract] [Full Text] [Related]
13. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
14. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
Adamska A; Domenichini A; Capone E; Damiani V; Akkaya BG; Linton KJ; Di Sebastiano P; Chen X; Keeton AB; Ramirez-Alcantara V; Maxuitenko Y; Piazza GA; De Laurenzi V; Sala G; Falasca M
J Exp Clin Cancer Res; 2019 Aug; 38(1):312. PubMed ID: 31378204
[TBL] [Abstract][Full Text] [Related]
16.
Wang F; Xia X; Yang C; Shen J; Mai J; Kim HC; Kirui D; Kang Y; Fleming JB; Koay EJ; Mitra S; Ferrari M; Shen H
Clin Cancer Res; 2018 Jul; 24(13):3176-3185. PubMed ID: 29602802
[No Abstract] [Full Text] [Related]
17. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
18. Chloroquine Potentiates the Anticancer Effect of Pterostilbene on Pancreatic Cancer by Inhibiting Autophagy and Downregulating the RAGE/STAT3 Pathway.
Chen RJ; Lyu YJ; Chen YY; Lee YC; Pan MH; Ho YS; Wang YJ
Molecules; 2021 Nov; 26(21):. PubMed ID: 34771150
[TBL] [Abstract][Full Text] [Related]
19. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
20. Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion.
Elliott IA; Dann AM; Xu S; Kim SS; Abt ER; Kim W; Poddar S; Moore A; Zhou L; Williams JL; Capri JR; Ghukasyan R; Matsumura C; Tucker DA; Armstrong WR; Cabebe AE; Wu N; Li L; Le TM; Radu CG; Donahue TR
Proc Natl Acad Sci U S A; 2019 Apr; 116(14):6842-6847. PubMed ID: 30894490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
